Latest Content


AmplifyBio Acquires PACT Pharma to Advance Cell and Gene Therapy Services

The contract and research organization (CRO) AmplifyBio has announced the acquisition of select assets from privately held biopharmaceutical company PACT Pharma Inc to advance its cell and gene therapy service offerings.
4th Oct 2022

Janssen Presents Positive Data from Two Ophthalmological Gene Therapy Programs

The Janssen Pharmaceutical Companies of Johnson & Johnson has presented primary results from two of its gene therapy studies at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting.
3rd Oct 2022

Looking to the Future of CAR-T Cell Therapy Manufacture

Ryan Cawood and Robert Leydon from OXGENE, a WuXi Advanced Therapies company, discuss current challenges and opportunities for discovery technologies for cell and cell-based therapies.
22nd Sep 2022

CAR-T Manufacturing Challenges and How to Overcome Them

For this Article, Phacilitate Editor, Georgi Makin, explores current challenges associated with CAR-T manufacturing workflows, considering how an integrated testing approach could reduce costs and accelerate speed to market.
22nd Sep 2022

Lentiviral Vector Manufacture and Testing: Challenges and Solutions

This article explores the challenges associated with lentiviral manufacture and testing, from logistical to technical scientific obstacles, and discusses potential solutions.
22nd Sep 2022

bluebird bio Receives Second FDA Approval for a Gene Therapy in Two Months with Skysona for CALD

bluebird bio’s Skysona has become the first therapy targeting early active cerebral adrenoleukodystrophy (CALD) to be approved, under an accelerated timeline, by the FDA.
20th Sep 2022

Don’t Miss Out on Our Next Webinar

Upcoming Event

Up Next: Can a Smaller Plasmid Produce Huge Benefits? The Power of Small

Optimizing gene payload begins with plasmid design.
08:00 PDT | 11:00 EDT | 16:00 GMT

Access Our Webinar Library

Our eBooks & Infographics
In this infographic, we have detailed some key considerations when choosing your plasmids for CAR-T development.
As we celebrate 10 years of CAR-T, the Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for CAR-T development.
Gaining market and patient access in Europe has presented many cell and gene therapy companies with barriers. The advanced therapies industry is currently facing a dilemma: scientific advancement is exceeding market and reimbursement adaptation.
Advanced therapies’ market access is a hot topic. Joining Phacilitate to shed some light on market access struggles are Director at NJ Redfern Limited and ex-bluebird bio UK GM Nicola Redfern, former SVP & CBO at Novartis Gene Therapies and current AviadoBio CEO Lisa Deschamps, and, Vice President and Global Head of Value and Access, at Novartis, Tay Salimullah.
What’s preventing developers from designing mechanistically relevant assays? This report examines this question, focusing on the identification and measurement of appropriate CQAs, the value of fit-for-purpose analytics technologies and what the future of CGT manufacturing analytics should look like.
May 2022 marks the month 17-year-old Emily Whitehead, the first pediatric patient in the world to receive CAR-T cell therapy, celebrates a momentous milestone: 10 years’ cancer free. All month Phacilitate will be joining to celebrate 10 years of CAR-T!
Welcome to Phacilitate’s first Women in Advanced Therapies eBook, commemorating International Women’s Day 2022.
A snapshot of the industry’s approach to commercialisation, presented as a handy infographic.
A collection of the outcomes from the roundtables and panels that took place at Advanced Therapies Connect 2020
This e-book examines 15 of the world’s leading immuno-oncology biotechnology companies, providing you with an at-a-glance view plus more detailed information on how their pipelines are developing.